To include your compound in the COVID-19 Resource Center, submit it here.

BMS reports CheckMate -142 data for Opdivo plus Yervoy in dMMR or MSI-H metastatic CRC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab plus Yervoy ipilimumab led to an objective response rate (ORR) of 55% among 119 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) in the Phase II CheckMate -142 trial. Data were presented at

Read the full 463 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE